Paroxetine suppresses 27-hydroxycholesterol-induced responses in THP-1 human monocytic cells by regulating the AKT/mTORC1 pathway
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-21 23:50
摘要：
Paroxetine (PRX) demonstrates significant immunomodulatory effects by suppressing 27-hydroxycholesterol-induced inflammatory responses in THP-1 human monocytic cells. The study reveals that PRX regulates key pathways, particularly the Akt/mTORC1 signaling pathway, which is crucial for modulating inflammation. Findings suggest that PRX could be repurposed for treating chronic inflammatory diseases, highlighting its potential as a novel therapeutic agent. Further research is warranted to explore its efficacy in clinical settings.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
PRX suppresses 27OHChol-induced CCL2 expression and migration.
PRX inhibits phosphorylation of Akt, S6, and 4E-BP1.
Study suggests PRX may offer a novel approach for targeting chronic inflammatory diseases.
真实性检查
否
AI评分总结
Paroxetine (PRX) demonstrates significant immunomodulatory effects by suppressing 27-hydroxycholesterol-induced inflammatory responses in THP-1 human monocytic cells. The study reveals that PRX regulates key pathways, particularly the Akt/mTORC1 signaling pathway, which is crucial for modulating inflammation. Findings suggest that PRX could be repurposed for treating chronic inflammatory diseases, highlighting its potential as a novel therapeutic agent. Further research is warranted to explore its efficacy in clinical settings.